ugichem GmbH is a biotech company, located in Innsbruck, Austria. The company has designed and developed novel cell membrane crossing and physiologically active antisense compounds ("Cell Membrane Crossing Oligomers, CMCOs"), which overcome the shortcomings of natural and other synthetic nucleic acid oligomers.

The company emerged from Professor Ugi´s group at the Technical University Munich´s Institute for Organic Chemistry. The first developments were supported from the business angels Elmar and Eva Zeising. In 2003, ugichem closed a Series A round of financing accompanied by a relocation of the company to Innsbruck, Austria. The Munich based venture capital firm, The BioScience Ventures Group AG, a specialist for providing risk management capital for early-stage biotechnology companies, was leading the financing round in partnersphip with The Austria Wirtschaftsservice GmbH (Vienna) through its Life Science Austria program and the Hypo Tirol Bank. Since 2007, the Swiss Business Angel Dr. Jürg Geigy is a further shareholder of ugichem.